SaiLong(002898)
Search documents
*ST赛隆董事长陈科等辞职
Bei Jing Shang Bao· 2025-10-08 08:32
Core Viewpoint - *ST Sailong (002898) announced the resignation of key executives, indicating potential shifts in company leadership and strategy [1] Group 1: Executive Resignations - Chairman and President Chen Ke resigned from the position of Chairman and Strategic Decision Committee Chairman due to work adjustments, but will continue as President, Director, and Committee Member [1] - Vice President and Board Secretary Zhang Xu resigned from the Vice President position for work adjustment reasons, but will remain as Board Secretary [1] - Vice President Duan Daifeng resigned from the Vice President position due to personal career development plans and will not hold any position in the company or its subsidiaries after resignation [1]
*ST赛隆:陈科辞去公司董事长及战略决策委员会主任委员职务
Mei Ri Jing Ji Xin Wen· 2025-10-08 07:49
Group 1 - The company *ST Sailong announced changes in its leadership, with Mr. Chen Ke resigning as Chairman and head of the Strategic Decision Committee, Ms. Zhang Xu resigning as Vice President while continuing as Secretary of the Board, and Mr. Duan Daifeng resigning as Vice President due to personal career development plans [1] - For the first half of 2025, *ST Sailong's revenue composition is as follows: 59.82% from the pharmaceutical manufacturing industry, 39.78% from the electronics industry, and 0.4% from other businesses [1] Group 2 - As of the latest report, *ST Sailong has a market capitalization of 2.5 billion yuan [2]
*ST赛隆(002898) - 关于公司董事长和高级管理人员辞职的公告
2025-10-08 07:45
因个人职业发展规划调整原因,段代风先生申请辞去公司副总裁职务,辞职 后,段代风先生将不在公司及子公司担任任何职务。截至本公告披露日,段代风 先生未持有公司股份,不存在应履行而未履行的承诺事项。 根据相关规定,董事长和高级管理人员的辞职报告自送达公司董事会之日起 生效,其辞任不会影响公司正常的生产经营。 陈科先生、张旭女士、段代风先生在公司任职期间恪尽职守、勤勉尽责,公 司对此表示诚挚的敬意和衷心感谢! 特此公告。 赛隆药业集团股份有限公司 证券代码:002898 证券简称:*ST 赛隆 公告编号:2025-082 赛隆药业集团股份有限公司 关于公司董事长和高级管理人员辞职的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚 假记载、误导性陈述或重大遗漏。 赛隆药业集团股份有限公司(以下简称"公司")董事会于近日收到公司董 事长兼总裁陈科先生、副总裁兼董事会秘书张旭女士、副总裁段代风先生的书面 辞职报告。具体情况如下: 因工作调整原因,陈科先生申请辞去公司董事长及战略决策委员会主任委员 职务,辞去上述职务后陈科先生继续担任公司总裁、董事、战略决策委员会委员。 截至本公告披露日,陈科先生未持有 ...
赛隆药业集团股份有限公司2025年第二次临时股东会决议公告
Shang Hai Zheng Quan Bao· 2025-09-29 21:42
登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、误导性陈述或重大遗 漏。 特别提示: 1.本次股东会无变更、取消、否决议案的情况; 2.本次股东会无变更以往股东会已通过决议的情况。 一、会议召开和出席情况 1.会议召开情况 (1)会议召开时间: 证券代码:002898 证券简称:*ST赛隆 公告编号:2025-080 赛隆药业集团股份有限公司 2025年第二次临时股东会决议公告 现场会议:2025年9月29日(星期一)15:00 网络投票时间:通过深圳证券交易所交易系统进行网络投票的具体时间为2025年9月29日上午9:15- 9:25,9:30-11:30,下午13:00-15:00;通过深圳证券交易所互联网投票系统进行网络投票的具体时间为 2025年9月29日9:15-15:00。 (2)会议召开地点:珠海市香洲区南湾北路31号2单元21层公司会议室。 (3)召开方式:以现场投票、网络投票相结合的方式召开。 (4)会议召集人:公司董事会。 (5)会议主持人:董事长陈科。 (6)会议召开的合法、合规性:本次会议的召集、召开和表决程序符 ...
*ST赛隆(002898) - 关于非独立董事补选完成的公告
2025-09-29 11:31
证券代码:002898 证券简称:*ST 赛隆 公告编号:2025-081 赛隆药业集团股份有限公司 关于非独立董事补选完成的公告 董事会 2025 年 9 月 30 日 附件: 一、非独立董事简历 赛隆药业集团股份有限公司(以下简称"公司")于 2025 年 9 月 29 日召开 2025 年第二次临时股东会,审议通过了《关于补选公司第四届董事会非独立董 事的议案》,同意选举殷惠军先生为公司第四届董事会非独立董事,任期自本次 股东会审议通过之日起至第四届董事会届满之日止,简历详见附件。 殷惠军先生能够胜任所聘岗位职责的要求,不存在《公司法》、《公司章程》 等法律法规规定的禁止任职的情形,不存在被中国证监会确定为市场禁入者且在 禁入期的情况,亦非失信被执行人。本次补选殷惠军先生担任公司第四届董事会 非独立董事不会导致董事会中兼任公司高级管理人员以及由职工代表担任的董 事人数总计超过公司董事总人数的二分之一以上的情形,且公司独立董事的人数 不少于董事会成员的三分之一。 二、备查文件 1.公司 2025 年第二次临时股东会决议。 特此公告。 赛隆药业集团股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、 ...
*ST赛隆(002898) - 关于赛隆药业集团股份有限公司2025年第二次临时股东会的法律意见书
2025-09-29 11:30
北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 8/9/11/F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.: 010-50867666 传真/Fax: 010-56916450 网址/Website: www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 昆明 南昌 北京市康达律师事务所 关于赛隆药业集团股份有限公司 2025 年第二次临时股东会的法律意见书 康达股会字【2025】第 0424 号 致:赛隆药业集团股份有限公司 根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民共和 国证券法》(以下简称"《证券法》")、《上市公司股东会规则》(以下简称"《股 东会规则》")以及《赛隆药业集团股份有限公司章程》(以下简称"《公司章程》") 的规定,北京市康达律师事务所(以下简称"本所")接受赛 ...
*ST赛隆(002898) - 2025年第二次临时股东会决议公告
2025-09-29 11:30
证券代码:002898 证券简称:*ST 赛隆 公告编号:2025-080 赛隆药业集团股份有限公司 2025 年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 特别提示: 1.本次股东会无变更、取消、否决议案的情况; 2.本次股东会无变更以往股东会已通过决议的情况。 一、会议召开和出席情况 1.会议召开情况 (1)会议召开时间: 现场会议:2025 年 9 月 29 日(星期一)15:00 网络投票时间:通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 9 月 29 日上午 9:15-9:25,9:30-11:30,下午 13:00-15:00;通过深圳 证券交易所互联网投票系统进行网络投票的具体时间为 2025 年 9 月 29 日 9: 15-15:00。 (6)会议召开的合法、合规性:本次会议的召集、召开和表决程序符合《公 司法》、《深圳证券交易所股票上市规则》等有关法律、行政法规、部门规章、 规范性文件和《公司章程》的规定。 2.会议出席情况 (1)出席会议的股东及股东授权委托代表 68 人,代表股份 40, ...
短线防风险 171只个股短期均线现死叉
Zheng Quan Shi Bao Wang· 2025-09-23 08:03
Market Overview - The Shanghai Composite Index closed at 3821.83 points, with a decline of 0.18% [1] - The total trading volume of A-shares reached 25,184.71 billion yuan [1] Technical Analysis - A total of 171 A-shares experienced a death cross, where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Innovation Medical: 5-day MA at 22.60 yuan, 10-day MA at 23.25 yuan, a difference of -2.80% [1] - Xiangyu Medical: 5-day MA at 54.48 yuan, 10-day MA at 55.33 yuan, a difference of -1.54% [1] - Northern Long Dragon: 5-day MA at 122.21 yuan, 10-day MA at 123.92 yuan, a difference of -1.38% [1] Stock Performance - Key stocks with notable declines include: - Innovation Medical: down 2.97% with a turnover rate of 16.99% [1] - Xiangyu Medical: down 5.95% with a turnover rate of 2.14% [1] - Northern Long Dragon: down 2.23% with a turnover rate of 20.67% [1] - Other stocks with significant declines include: - Aorui: down 5.25% [1] - Changbai Mountain: down 7.15% [1] - Hengbao Shares: down 6.73% [1]
短线防风险 228只个股短期均线现死叉
Zheng Quan Shi Bao Wang· 2025-09-23 04:37
Market Overview - The Shanghai Composite Index closed at 3781.61 points, with a decline of 1.23% [1] - The total trading volume of A-shares reached 1713.539 billion yuan [1] Technical Analysis - A total of 228 A-shares experienced a death cross, where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Innovation Medical: 5-day MA at 22.55 yuan, 10-day MA at 23.23 yuan, a difference of -2.92% [1] - North Long Dragon: 5-day MA at 121.67 yuan, 10-day MA at 123.65 yuan, a difference of -1.60% [1] - Xiangyu Medical: 5-day MA at 54.49 yuan, 10-day MA at 55.34 yuan, a difference of -1.53% [1] Individual Stock Performance - Significant declines in stock prices include: - Innovation Medical: down 4.27% with a turnover rate of 14.36% [1] - North Long Dragon: down 4.52% with a turnover rate of 13.85% [1] - Xiangyu Medical: down 5.86% with a turnover rate of 1.42% [1] - Other notable declines: - Shandong Mining Machine: down 4.43% [1] - Huakang Clean: down 6.50% [1] - Beautiful Ecology: down 5.15% [1] Additional Stock Data - The following stocks also showed significant declines: - Yuyin Co.: down 5.46% [2] - Kexin Information: down 5.22% [1] - Visual China: down 3.88% [1] - Stocks with notable trading activity include: - Hengbao: down 6.64% with a turnover rate of 10.88% [2] - Changbai Mountain: down 6.53% with a turnover rate of 4.05% [2]
调研速递|赛隆药业接受线上投资者调研,聚焦业务布局与发展规划
Xin Lang Cai Jing· 2025-09-19 12:29
Group 1 - The company held an online investor interaction session on September 19, 2025, where key executives addressed various investor inquiries regarding restricted stock release, business layout, asset acquisitions, shareholder numbers, and stock price stability [1][2][3] - Regarding the restricted stock release, the company stated that according to the Shenzhen Stock Exchange's regulations, there are restrictions on the transfer of shares by directors and senior management during their term and for six months after [1] - The company has launched its Xinjiang factory and strategically entered the AI server business, achieving revenue of 53.98 million yuan from AI server operations during the reporting period, aiming to become a provider of integrated solutions for high-performance AI servers [1] Group 2 - The company currently has no plans for issuing shares to purchase assets, major asset restructuring, or acquisitions, and will disclose any future developments in a timely manner [2] - To ensure fair information disclosure, the company will report shareholder numbers in its regular reports, and it is focused on improving its main business and creating new profit growth points to address stock price declines [3] - The board of directors has approved a proposal to amend the company's articles of association to add the position of vice chairman, which still requires shareholder meeting approval [3]